Two recent clinical trials tested a new drug, GDC-0449, that inhibits the Hh signalling pathway by targeting Smo, in advanced basal-cell carcinoma and medulloblastoma (Rudin et al, 2009; Von Hoff et al, 2009). The gene discussed is SMO; the disease is medulloblastoma.